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ABSTRACT
The transcription factor (TF) Sp1 is a well-known
RNA polymerase II transcription activator that binds
to GC-rich recognition sites in a number of essential
cellular and viral promoters. In addition, direct inter-
ference of Sp1 binding to DNA cognate sites using
DNA-interacting compounds may provide promising
therapies for suppression of cancer progression
and viral replication. In this study, we present a
rapid, sensitive and cost-effective evaluation of a
GC intercalative drug, doxorubicin (DOX), in disso-
ciating the Sp1–DNA complex using fluorescence
correlation spectroscopy (FCS) in a microfluidic
system. FCS allows assay miniaturization without
compromising sensitivity, making it an ideal ana-
lytical method for integration of binding assays
into high-throughput, microfluidic platforms. A poly-
dimethylsiloxane (PDMS)-based microfluidic chip
with a mixing network is used to achieve specific
drug concentrations for drug titration experiments.
Using FCS measurements, the IC50 of DOX on the
dissociation of Sp1–DNA complex is estimated to be
0.55 mM, which is comparable to that measured by
the electrophoretic mobility shift assay (EMSA).
However, completion of one drug titration experi-
ment on the proposed microfluidic-FCS platform is
accomplished using only picograms of protein and
DNA samples and less than 1 h total assay time,
demonstrating vast improvements over traditional
ensemble techniques.
INTRODUCTION
The transcription factor (TF) Sp1, a member of a large family
of zinc ﬁnger proteins, was ﬁrst identiﬁed in HeLa cells based
on its ability to activate the SV40 early promoter (1,2).
Subsequently, the ubiquitously expressed Sp1 has been indi-
cated in transcriptional activation of a wide variety of genes
through selective binding to a GC-rich DNA sequence
(GC box). Furthermore, synergistic or direct interactions
with several other TFs and cell-cycle regulatory proteins
have revealed a complex role for Sp1 in mediation of trans-
cription of many cellular genes during development (3,4) and
of over-expressed genes during tumor growth (5,6). Still, pre-
vious studies have revealed that host Sp1 protein binding is
critical for transcriptional regulation of several viral genes
in both herpes simplex virus type 1 (HSV-1) and human
immunodeﬁciency virus type 1 (HIV-1) (7,8). Not surpris-
ingly, this information led to studies aimed at developing
antitumoric and antiviral compounds designed to disrupt
Sp1-dependent gene expression in cancerous and infected
cells. Speciﬁcally, HIV replication in cultured cells was sup-
pressed by using mutation-insensitive DNA-interacting drugs
to inhibit HIV Tat transactivation by blocking Sp1 binding at
GC boxes on the long terminal repeat (LTR) promoter (7,8).
Similarly, growth arrest and cellular apoptosis of cancer cells
were induced by inhibiting Sp1-dependent Cdc2 and survivin
expression (5,6,9).
Mechanistically, these DNA-interacting drugs resemble
TFs in their preference for DNA sequences and groove orien-
tations and prevent formation of TF–DNA complexes either
by directly competing with the TF for the same DNA sites
or by indirectly inducing DNA conformational changes.
Several studies have been carried out to evaluate the effects
of DNA-interacting drugs as inhibitors of the Sp1–DNA
complex using electrophoretic mobility shift assay (EMSA)
coupled with radioactive-based detection (5–8,10–13). How-
ever, utilizing EMSA as the primary method of evaluating
drug-induced disruption of TF–DNA complexes presents a
number of drawbacks, including time-consumption, reagent-
consumption, and lack of quantiﬁcation. For example, in
order to clearly resolve the bands in EMSA, several tens of
nanograms of TF are needed to saturate binding sites on the
nanograms of DNA required per well, thereby imposing a
high reagent cost on this assay. These requirements make
EMSA applicable only to abundantly expressed TFs. More
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and TF–DNA complex disruption may occur due to the gel
pore size and buffer conditions during electrophoresis, lead-
ing to underestimated protein binding activity (14–16). To
overcome these and many more limitations, an assay that
allows fast, accurate and reproducible determination of TF
bindings at a single-molecule level is increasingly in demand.
Fluorescence-based methodologies, such as time-resolved
ﬂuorescence, ﬂuorescence anisotropy, ﬂuorescence resonance
energy transfer (FRET), ﬂuorescence intensity distribution
analysis (FIDA) and ﬂuorescence correlation spectroscopy
(FCS), play an increasingly important role in allowing
rapid and accurate determination of receptor-ligand binding
fractions in an equilibrium, homogeneous and separation-
free format (17–22). Unlike most of the ﬂuorescence methods
that are based on ensemble emission average, FCS is a
technique that allows the ﬂuorescence measurements to be
carried out in a nanoscale domain with single-molecule
resolution (23–29). In FCS measurements, the temporal
ﬂuctuations of ﬂuorescence signal detected from ﬂuorescent
molecules diffusing through a femtoliter-sized detection
volume are analyzed via an autocorrelation function, provid-
ing the kinetic information required to monitor changes in
the molecular states and the concentration of ﬂuorescent
molecules (30–32). Due to the nature of the femtoliter-sized
detection volume, FCS may allow miniaturization of assay
volume without comprising assay sensitivity (19–22). There-
fore, FCS is well suited to be incorporated in a microﬂuidic
format, achieving rapid, highly sensitive and cost-effective
analysis.
This report describes a binding assay platform that
implements FCS on a microﬂuidic titration chip for the
study of the displacement of Sp1 from the Sp1–DNA
complex by a GC-intercalative agent, doxorubicin (DOX).
The titration chip combines a microﬂuidic mixing network
(33) with a valving system created using a multilayer soft
lithography process (34–36) to generate drug solutions of
varying concentrations; expose Sp1–DNA complexes to
these drug dilutions; and separate each combination into
nanoliter-sized interrogation chambers. Quantitative evalu-
ation of Sp1-DNA binding inhibition by DOX is then
accomplished by FCS measurements directly on the chip.
In this report, we ﬁrst characterize the FCS detection scheme
in resolving the correct binding fractions of a controlled DNA
binary-mixing system. The binding afﬁnity (Kd) of the Sp1–
DNA interaction (32 nM) is then discerned based on the same
FCS analysis scheme. Second, FCS measurements are carried
out inside polydimethylsiloxane (PDMS) microchambers
containing 300 nl to 10 pl DNA samples to validate that
FCS is indeed insensitive to miniaturized sample volumes.
Third, a dose-response curve of DOX on Sp1-DNA inhibition
is compiled using the proposed microﬂuidic-FCS platform
and used to determine the concentration of DOX required
to give 50% Sp1 binding inhibition (IC50). The IC50 (0.55
mM) generated by the FCS measurements agrees well with
the semi-quantitative EMSA data previously provided in lit-
erature (10). However, the advantages of this chip-based
FCS technology are obvious. For example, drug titration on
the microﬂuidic platform requires only 300 pg of Sp1 and
15 pg of DNA fragments, and the evaluation on drug potency
is completed within 1 h.
MATERIALS AND METHODS
Oligonucleotides and Sp1
The DNA target for Sp1-binding experiments was a 23 bp
DNA fragment [Cy5-ACTTTCCAGGGAGGCGTGGCCTG,
M.W. 14.6 kDa, Sp1-binding site underlined (37,38)] span-
ning from  87 to  65 nt of the HIV LTR promoter (7,8).
This dsDNA target was formed by annealing of two high per-
formance liquid chromatography (HPLC)-puriﬁed synthetic
ssDNA (Integrated DNA Technology), one of which was
50-end labeled with a Cy5 dye. Hybridization was carried
out in 5 mM Tris–HCl (pH 8.0) buffer where the temperature
was slowly cooled down from 95 C to room temperature. The
truncated Sp1 protein (M.W. 17 kDa) was overproduced from
a bacterial Rop expression system that consisted of 530–685
amino acids of the C-terminal, three zinc-ﬁnger DNA-binding
domains (1). The protein was puriﬁed to 95% homogeneity.
The DNA binding capability of this completely refolded
recombinant Sp1 was ﬁrst veriﬁed using EMSA before fur-
ther testing with the FCS system. The reason for using this
truncated Sp1 was to allow a clear Sp1-DNA binding band
in EMSA. Doxorubicin hydrochloride (Sigma–Aldrich,
M.W. 580 Da) was prepared in dimethyl sulfoxide (DMSO)
and stored at 4 C.
FCS setup
FCS measurements were carried out with a custom-built
inverted confocal ﬂuorescence spectroscope (39,40). A
He-Ne (633 nm, 25-LHP-151-249, Melles Griot) laser was
used to excite the Cy5 dyes. The laser beam was expanded
to  5 mm in diameter by a telescope and was reﬂected
by a dichroic mirror (51008 BS, Chroma Technology) into
a microscope objective (100 · N.A. 1.3, oil immersion,
UPlanFl, Olympus). Fluorescence emitted from the sample
was collected with the same objective (epi-illumination)
and passed though a 50 mm pinhole (PNH-50, Melles Griot)
installed in an image plane of the microscope to eliminate
out-of-focus signal. A band pass ﬁlter (670DF40, Omega
Optical) was used to reduce the background signal and the
ﬁltered ﬂuorescence light was then focused onto an avalanche
photo diode (SPCM-AQR-13, PerkinElmer). The output
electronic signal was fed into a correlator (ALV-5000/EPP,
ALV-GmbH) to compute the autocorrelation functions. The
power of the laser was adjusted to 100 mW by a neutral den-
sity ﬁlter before entering the objective. This power level
resulted in good ﬂuorescence signals, but was low enough
to keep photobleaching of Cy5 negligible (41,42). The half
radii of the detection volume were determined to be
 0.4 mm in x-y and 4 mm in z directions, respectively, by
ﬁtting the autocorrelation function of free Cy5 in water,
assuming a 3D Gaussian-shaped detection volume and a
diffusion coefﬁcient of D ¼ 2.5·10
 6 cm
2/s (41,43). The
laser beam was focused 10 mm into the sample and was
controlled by a piezo-actuator with sub-micron resolution
(P-517.3CL, Physik Instrumente) for all FCS measurements
in this report.
Analysis of FCS data
When only one type of ﬂuorescent species is present,
for instance, the labeled DNA alone, the analysis of the
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ﬁt using the following one-component analytical model
(41,44):
GðtÞ¼
1
N
gDðtÞXðtÞ 1
Here N is the average number of light-emitting particles
diffusing in the detection volume and gD(t) is the auto-
correlation function arising from ﬂuorescence ﬂuctuations
due to translational diffusion. The analytical expression for
gD(t) based on diffusion through a Gaussian-shaped detection
volume often ﬁts poorly to the experimental FCS curves,
possibly due to spherical aberration of the objective or the
distorted excitation proﬁle resulted from the increased laser
power (45,46). In order to account for these effects and to
better ﬁt the FCS curves, a semi-empirical expression,
which has a form similar to that of anomalous diffusion inside
living cells (47,48), is used here to describe gD(t):
gD ¼

1
1 þðt
td Þ
a

‚ 2
where a is the anomalous factor. X(t) represents the ﬂuctua-
tions in the fast time range due to triplet-state relaxation and
trans-cis isomerization of Cy5 dye and is deﬁned by (41,42):
XðtÞ¼
1   F þ Fe
  t
tr
1   F
3
F is the fraction of molecules in non-ﬂuorescent states and tr
is the relaxation time.
In the presence of two types of ﬂuorescence species, for
instance, the free DNA and the Sp1-bound DNA, the molar
fraction of the second species (e.g. the Sp1-bound DNA),
Y, can be determined using the following two-component
analytical model (19,23,44):
GðtÞ¼
1
N
½ð1   YÞgF‚DXF þ YQ2gB‚DXB ‚ 4
where Q is the relative brightness of the bound species
compared to the free, unbound species. The subscripts F
and B denote the free and bound species, respectively. The
molar fraction of Sp1-bound DNA, Y, can also be regarded
as the degree of binding in Sp1-DNA binding experiments.
The least-squares ﬁt used in this report is based on
the Levenberg–Marquardt algorithm within Origin 7.0
(OriginLab).
Sp1-DNA binding experiments
Samples for Sp1-DNA binding experiments contained 5 nM
Cy5-labeled dsDNA fragment and 10–120 nM truncated
Sp1 in a buffer with 10 mM Tris–HCl (pH 7.5), 25 mM
NaCl, 2.5 mM MgCl2,2 5mM ZnSO4, 0.05% NP-40, 7 mM
2-mercaptoethanol and 250 mg/ml BSA (1 · Sp1-DNA bind-
ing buffer). The reaction samples were incubated for 10 min
at room temperature before FCS measurements. The diffusion
times and other FCS parameters were ﬁrst determined for the
free DNA and DNA bound with Sp1 by saturating the DNA
with a high concentration of Sp1. FCS parameters used in
two-component analysis are listed in Table 1.
Fabrication of microfluidic chips
Microﬂuidic titration chips were fabricated based on a multi-
layer soft lithography process (34–36). Two layers of PDMS
structures were constructed, one for sample delivery and
processing and the other for mechanical on-off valving
(Figure 1). For the sample delivery (ﬂuidic) layer, SJR5740
(Shipley) was used as the mold material and was patterned
in bas-relief on a 400 silicon wafer using a standard photo-
lithography process. After a reﬂow process at 180 Co na
hotplate for 30 min, the resist mold had a semi-circular
cross section ( 15 mm tall). For the mechanical valving
layer, SU-8 2025 (MicroChem) was used to make a 20 mm
tall mold. PDMS prepolymer (mixing ratio ¼ 1:7, Sylgard
184, Dow Corning) was cast on the SU-8 valve masters to
reach a thickness of   4 mm and cured thermally at 80 C
in an oven for 9 min. Silicon wafers with SJR5740 channel
molds were silanized in a desiccator with vapor of
chlorotrimethylsilane (Sigma–Aldrich). PDMS prepolymer
(mixing ratio 1:15) was spin-coated on the SJR5740 channel
masters at 2000 rpm for 60 s, followed by a thermal curing at
85 C in an oven for 6 min. The cured PDMS sheet containing
mechanical valves was ﬁrst peeled away from the SU-8
silicon master and cut into a proper chip size. The hole for
the valve control inlet was formed by punching through the
PDMS sheet using a syringe needle (McMaster-Carr). This
valve PDMS sheet was then placed on top of the cured
PDMS ﬂuidic layer, which was still on the SJR5740 silicon
master. The two layers were fused together by baking the
wafer at 85 C in an oven for 25 min. The fused PDMS sheets
were peeled from the silicon master together and cut into
proper chip size. The holes for the sample inlets and outlets
were formed again using a syringe needle. The microﬂuidic
chip was completed by plasma oxidation of the PDMS
surface and irreversible sealing to a 170 mm-thick glass
slide. The samples were delivered to the microﬂuidic chip
via a 1 ml syringe and 0.02 inch I.D. Tygon  tubing
(Cole-Parmer) ﬁtted with 23-gauge steel needle tips
(McMaster-Carr). The sample injection rate was controlled
by a syringe pump (PHD 2000, Harvard Apparatus).
Separately, an array of microchambers of varying sizes
for evaluating the performance of FCS in miniaturized
assay volumes were patterned on a PDMS sheet using the
above described SU-8 molding process. The DNA sample
was sandwiched between a microscope slide and a patterned
PDMS sheet containing various sized microchambers, follow-
ing the procedure described by Rondelez et al. (49). Excess
sample was squeezed out by applying pressure to the
Table 1. Parameters used in two-component FCS analysis
td (ms) F tr (ms) a Q
(1) In DNA binary-mixing experiment:
dsDNA 344 0.149 18 0.95 0.616
ssDNA 241 0.326 14 0.93
(2) In Sp1-DNA binding experiment:
DNA 344 0.149 18 0.95 0.719
Sp1-DNA 431 0.151 18 0.93
Symbols: td, diffusion time; F, fraction of fluorescent molecules in non-
fluorescent states; tr, relaxation time; a, anomalous factor; Q, relative
brightness.
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van der Waals forces.
Drug titration experiment on PDMS microfluidic chip
DOX solutions at three different concentrations were intro-
duced to inlets on the upper part of the microﬂuidic titration
chip (Figure 1) and the Sp1-DNA mixture was introduced to
the single inlet on the lower part of the chip. The concen-
trations chosen for DOX injection were 0 (1 · Sp1-DNA
binding buffer only), 40 nM and 4 mM, respectively. The
Sp1-DNA mixture, which contained 10 nM DNA fragments
and 160 nM Sp1, was incubated at room temperature for
10 min prior to injection into the microchannels, which
were ﬁrst ﬂushed with 1 mg/ml BSA in HEPES buffer for
20 min to prevent protein adsorption on the PDMS surface
(44,49,50). The diluted DOX solutions were then injected
into the microchannels at a ﬂow rate of 0.1 ml/min and the
Sp1-DNA mixture was injected at a ﬂow rate three times
that of the DOX. The serpentine channels within the micro-
ﬂuidic network enhanced mixing either between the neigh-
boring streams of the DOX solutions or between the diluted
DOX solutions and the Sp1-DNA mixtures.
After samples within the mixing network reached a steady-
state ﬂow, the two mechanical valves were simultaneously
turned on to ‘close’ the FCS interrogation chambers by
applying   20 psi of compressed air to the valve inlet (valves
were primed with water), thus isolating the Sp1-DNA com-
plexes mixed with various amounts of DOX in eight different
interrogation chambers, each containing a volume of   3 nl.
After incubation for 10 min, FCS measurements were taken
inside each of the eight microchambers.
Drug titration experiment using EMSA
A DOX titration experiment was carried out using EMSA as a
proof to validate the proposed microﬂuidic-FCS platform.
The reaction samples for EMSA contained 10 mM Tris–
HCl (pH 7.5), 25 mM NaCl, 2.5 mM MgCl2,2 5mM
ZnSO4, 0.05% NP-40, 7 mM 2-mercaptoethanol, 250 mg/ml
BSA, 10% glycerol, 1 ng
32P-labeled DNA fragment, and
20 ng Sp1 per each 15 ml reaction. DOX was added to the
reaction to give an appropriate ﬁnal DOX concentration for
the reaction volume of 15 ml. After incubation for 10 min
at room temperature, electrophoresis was performed in a
5% non-denaturing polyacrylamide gel using TBE buffer
[89 mM Tris base, 89 mM boric acid and 1 mM EDTA
(pH 8.0)] with each lane receiving 7 ml of each reaction
volume.
RESULTS
FCS analysis for determining binding fractions
In order to evaluate the two-component analytical model
(Equation 4) in determining molecular binding fractions, an
experiment analyzing binary mixtures of labeled ssDNA
and its dsDNA hybrid with FCS was performed. The 23 bp,
Cy5-labeled dsDNA hybrid was mixed with the 23 nt,
Cy5-labeled ssDNA (M.W. 7.6 kDa) to obtain different
molar fractions of dsDNA to total DNA (R: [dsDNA]/
([dsDNA]+[ssDNA])), simulating various binding fractions
(Y: the fraction of Cy5-labeled DNA strand forming duplex).
The total DNA concentration was ﬁxed at 5 nM in each mix-
ture and diffusion times (td) and other FCS parameters (F, tr,
a) were ﬁrst determined using the one-component model
(Equation 1) for samples containing only ssDNA or dsDNA
(Table 1). The relative brightness (Q) of dsDNA to ssDNA
was estimated to be 0.616 from ﬂuorescence intensity anal-
ysis. These parameters were then used in the two-component
model (Equation 4) to analyze the autocorrelation curves
measured from the binary mixtures in order to derive Y in
each sample. As shown in Figure 2A, the measured (Y) values
agree well with the mixing (R) values, showing the high
accuracy achieved by this two-component FCS analysis in
Figure 1. The PDMS-based microfluidic chip used for investigation on the
dissociation of Sp1–DNA complex by DOX. (A) The layout of microchannels
(red) and the mechanical on-off valves (blue). (B) A zoom-in of the mixing
portion on the microfluidic chip: a serpentine channel is used for enhancing
the mixing of the drug solution and the Sp1-DNA mixture. The interrogation
chamber has the size of  3 nl and can be isolated by simultaneously closing
the two valves to stop the flow in microchannels.
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the normalized autocorrelation curves measured from some
of the binary-mixing samples.
Sp1-DNA binding affinity measurements
A titration experiment was performed to determine the bind-
ing afﬁnity of Sp1 to its consensus DNA-binding site. Six
100-sec measurements were taken from 10 samples, which
contained ﬁxed amount of DNA fragments (5 nM) and
various amounts of Sp1 (10–120 nM). The relative brightness
(Q) of Sp1–DNA complex to free DNA was estimated to be
0.719 from ﬂuorescence intensity analysis. The resulting
binding fractions from two-component FCS analysis at each
Sp1 concentration were plotted in Figure 3, which yields an
afﬁnity Kd of 32 ± 2 nM from a hyperbolic ﬁt. This result
is in good agreement with the afﬁnity estimated from
EMSA (51).
FCS results versus assay volumes
To evaluate the potential of using FCS in miniaturized assay
volumes, we performed FCS measurements in an array of
PDMS microchambers of volumes decreasing from microliter
to picoliter. Experiments were made to determine DNA dif-
fusion times with FCS using a sample containing dsDNA
fragments at 5 nM. As shown in Figure 4, the measured val-
ues of DNA diffusion times were found consistent despite
decreasing assay volumes. The measured diffusion times
remained nearly unchanged even when the chamber size
was reduced down to 30 pl. Yet, when a chamber of 10 pl
was used for measurements, a decreased diffusion time
Figure 2. (A) Validation of the two-component FCS model using a DNA
binary-mixing system. R: the mixing molar fraction of dsDNA to total DNA.
Y: the measured molar fraction of Cy5-labeled DNA strand forming duplex.
The dash line represents the situation of Y equal to R and the filled circles
represent the measured Y at each R. Error bars represent standard deviations
from six FCS measurements. (B) Normalized autocorrelation curves
measured from five binary-mixing samples (R ¼ 0, 0.5, 0.75, 0.875 and 1).
Figure 3. DNA-binding fractions at various Sp1 concentrations characterized
by FCS measurements and the two-component analysis. The solid curve
results from a hyperbolic fit, yielding a binding constant of Kd ¼ 32 ± 2 nM.
Error bars represent standard deviations from six FCS measurements.
Figure 4. Diffusion times of the 23 bp DNA fragment measured using FCS in
nanoliter to picoliter-sized microchambers. Bulk measurements are carried
out in a 20 ml chambered glass plate. Error bars represent standard deviations
from six FCS measurements.
PAGE 5 OF 9 Nucleic Acids Research, 2006, Vol. 34, No. 21 e144accompanied by an increased deviation was noted, possibly
due to interference of the illumination and collection light
paths from the small chamber opening at this volume scale.
This result demonstrates that FCS assays are well suited
for assay miniaturization and can be performed at an assay
volume of sub-nanoliter or smaller without compromising
analysis integrity.
Drug evaluation using FCS on titration chip
We incorporated a design using triple inlets in the micro-
ﬂuidic mixing network for the titration experiment as this
design allowed generation of varying concentrations of
analyte spanning nearly three orders of magnitude in the
outlet channels (33). The length of the serpentine channels
(10 mm) was sufﬁciently long to allow full mixing of the
neighboring ﬂuid streams, given the ﬂow speed of drug
solutions ( 3 mm/s) and the estimated diffusion coefﬁcient
of the drug ( 5·10
 6 cm
2/s). The relative concentrations in
the downstream channels were measured through ﬂuores-
cence imaging with high-concentration ﬂuorescein and
through single-molecule counting with low-concentration
Cy5 dyes (Figure 5A and 5B), which both showed good
agreement with the analytical result calculated based on the
scheme described in literature (33). For the DOX titration
experiment, eight different DOX solutions of varying concen-
trations were generated in the downstream channels (0,
11.7 nM, 214 nM, 604 nM, 1.18 mM, 1.94 mM, 2.88 mM
and 4 mM, respectively) when introducing three DOX solu-
tions at concentrations of 0, 40 nM and 4 mM. After mixing
with the incoming solutions of Sp1-DNA mixtures at a
controlled ﬂow rate, the ﬁnal concentration of DOX in the
eight interrogation chambers were 0, 5.9 nM, 107 nM,
302 nM, 0.59 mM, 0.97 mM, 1.44 mM and 2 mM, while the
concentrations of Sp1 and DNA were 80 and 5 nM, res-
pectively. Figure 6A shows the dose-response curve of
DOX in the Sp1-DNA inhibition experiment. The IC50 of
DOX on the dissociation of Sp1–DNA complex, derived
from a dose-response ﬁt of the binding curve, was determined
to be 0.55 mM, which was comparable to that derived from
the EMSA result (Figure 6B) and the value reported in
literature (10).
DISCUSSION
Fast and cost-effective means of characterizing drug-target
interactions is of considerable importance in pharmaceutical
discovery. To address this requirement, we have developed
a semi-automatic titration platform for mechanistic analysis
of drug–protein–DNA interactions by implementing a rapid
FCS detection scheme in a low-volume, microﬂuidic format.
We have demonstrated that FCS was insensitive to assay
Figure 5. Characterization of concentration gradients generated by the
Christmas tree-like microfluidic mixing network with three inlets at relative
fluorophore concentrations of 0, 1 and 100. (A) Fluorescence micrographs
of solution gradients of fluorescein at serpentine mixing channel regions.
(B) Concentration gradients determined from analytical model ( ) and from
single-molecule counting ( ). Error bars represent standard deviations from
four measurements.
Figure 6. (A) The dose-response titration curve of DOX on the dissociation
of Sp1–DNA complex. FCS measurements are carried out on a PDMS
titration chip. IC50, the DOX concentration required to give 50% Sp1 binding
inhibition, is estimated to be 0.55 mM. Error bars represent standard
deviations from five FCS measurements. (B) Dox titration experiment using
EMSA. The gel result also indicates the IC50 around 0.5 mM.
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results of diffusion times when reducing the assay volume
down to the sub-nanoliter regime. In the current titration
experiment, the total volume of reagents required for ﬁlling
the microchannels and the interrogation chambers on the
chip are  300 nl for drug solutions and  100 nl for
Sp1-DNA mixture. As a result, this experiment consumes
only 300 pg of Sp1 and 15 pg of DNA, as opposed to hun-
dreds of nanograms of protein and DNA that are required
by conventional EMSA (7,8,10,11). In addition, the overall
assay time of the microﬂuidic FCS platform is much shorter
than that of EMSA ( 10 h) and the results are more quan-
titative due to the large amount of parameters and kinetic
data acquired in the FCS measurements. Further reduction
in reagent consumption per assay can be achieved by using
a titration chip that incorporates interrogation chambers of
further reduced sizes and allows automatic multiplexed
assays with shared ﬂuid inputs and delivery channels. Further
reduction in run time can also be achieved by using a highly
integrated FCS setup with parallel detection capability (52).
A commonly cited disadvantage of using FCS for binding
assay is the requirement of at least 5-to 8-fold increase in
mass (19,53) or 1.6-fold increase in diffusion time (44) on
binding in order to clearly differentiate the unbound species
from the bound one. In this report, we achieve for the
ﬁrst time using FCS in differentiating between a ssDNA
(M.W. 7.3 kDa) and its dsDNA hybrid (M.W. 14.6 kDa) in
solutions. When measuring their binary mixtures, the error
between the measured molar fraction, Y, and the mixing
molar fraction, R, is found to be less than 0.02 (Figure 2A).
Similar results have been demonstrated when analyzing
Sp1-DNA binding, where the binding-induced mass increase
is only 2.16 fold. Multiple experimental factors are thought
to contribute to this expansion of previously cited limits
of FCS as an analytical technique. First, FCS measurements
are strongly weighed in favor of the brighter component
(e.g. the unbound species) and the proper selection of relative
brightness, Q, in two-component FCS analysis (Equation 4)
is critical in order to obtain precise binding fractions
(see Supplementary Data) (19,23,44). Second, as aforemen-
tioned, a semi-empirical expression for gD(t) (Equation 2)
is used to better ﬁt the experimental FCS curves, allowing
more accurate binding fraction analysis and resulting in a
smaller standard deviation among measurements (data not
shown). Similar strategies using different gD(t) expressions
are also seen in literature (45,46). Third, the fast-relaxation
processes [X(t), Equation 3] of Cy5 dye contribute to an
additional shoulder in the microsecond region of the FCS
curve. Due to variation in the fractions of ﬂuorescent mole-
cules in non-ﬂuorescent states (F, see Table 1), the shape
of this fast-relaxation shoulder in Cy5-ssDNA autocorrelation
curve looks different from that in Cy5-dsDNA curve. This is
believed to enlarge the ‘window’ between the two FCS
single-species curves (Figure 2B), leading to a more accurate
binding fraction determination. However, in the case of
Sp1-DNA binding, the F value stays almost unchanged for
the bound species. This is believed to result in a larger stan-
dard deviation in the Sp1 binding system (Figure 3) compared
to that in the DNA binary-mixing system (Figure 2A). In
addition, the reliability of FCS measurements is found to
be improved by using Cy5, possibly due to the very low
autoﬂuorescence background signal from solvent near the
Cy5 emission wavelengths.
Variations of the microﬂuidic network used in this report
have been utilized previously in literature for generating
multiple concentrations of biomolecules for use in biomedical
assays and applications (54,55). By combining a microﬂuidic
mixing network with a downstream valving system, fabri-
cated using a multilayer soft lithography process, we have
made a novel titration chip for analysis of drug-target interac-
tion with FCS. The valve design allows isolation of samples
inside a nanoliter-sized interrogation chamber and facilitates
the kinetic study of molecules in a purely diffusion-governed
environment. Surface adsorption of assay reagents to device
materials is a complication unique to microﬂuidic-based
assays and arises due to the skewed surface-to-volume ratios
within microdevices compared to their macroscopic counter-
parts (49). However, this surface adsorption issue can be
resolved by surface blocking rinses (1 mg/ml BSA in
HEPES buffer) prior to use, ensuring a bioassay-compatible
microﬂuidic device.
The generally accepted Sp1 core consensus site as proposed
by Kadonaga et al. is GGGCGG (1). However, slight differ-
ences in recognition sequences for Sp1 that lack the core con-
sensus but retain function are often seen in various promoter
regions. GGGAGG is one of such sequences found in cardiac
actin promoter (37) and HIV LTR promoter (8). Both of our
EMSA and FCS results indicate that Sp1 bound strongly to
this GGGAGG site, agreeing with the reports from other
laboratories (8,37,38). Non-covalently binding drugs interact
with DNA in one of two ways as intercalative agents, such
as DOX described in the present study or as minor and/or
major groove binders (10,13). Kinetics and modes of the bind-
ing by these two types of drugs are different. Beyond the
model type of study, the proposed microﬂuidic-FCS platform
may also be applied to investigate the binding of Sp1 or other
TFs to different DNA-binding sites and possibly to examine
the interaction of groove-binding drugs to DNA targets
directly. Finally, the microﬂuidic-FCS method presents a ver-
satile technology platform and in addition to the study of
drug–protein–DNA interactions exempliﬁed in this report,
this new platform can be generally applied to study other
types of molecular bindings, such as protein–ligand and
protein–protein interactions.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.
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